Moleculin Biotech (MBRX) Financials

The income statement of Moleculin Biotech Inc (MBRX) provides a comprehensive overview of the company's financial performance. It shows the revenue generated by the company during a specific period, as well as the expenses incurred in generating that revenue. The net income from stockholders is the amount of profit left after deducting all expenses from the revenue. This gives investors an idea of how much profit the company has made.

The balance sheet of Moleculin Biotech Inc (MBRX) is a snapshot of the company's financial position at a specific point in time. It shows the company's total assets, including cash equivalents and other valuable holdings. It also shows the company's liabilities, including any debt it may have. The stockholders' equity is the amount of ownership the stockholders have in the company.

The cash flow statement of Moleculin Biotech Inc (MBRX) provides insights into the company's cash inflows and outflows. It shows the operating cash flow, which is the cash generated from the company's core operations. It also shows the investing cash flow, which is the cash used for acquiring or disposing of long-term assets. Additionally, it shows the financing cash flow, which is the cash used for funding the company's operations.

The EBIT (earnings before interest and taxes) of Moleculin Biotech Inc (MBRX) is a measure of the company's profitability before considering the impact of interest and taxes. It gives investors an idea of how much profit the company has generated from its core operations. The EBITDA (earnings before interest, taxes, depreciation, and amortization) is another measure of profitability that does not consider non-cash expenses like depreciation and amortization. These metrics help investors assess the company's financial performance.

The gross profit of Moleculin Biotech Inc (MBRX) is the revenue generated by the company minus the cost of goods sold. It represents the amount of money left over after deducting the direct costs associated with producing the goods or services. This figure is important because it shows the company's ability to generate profit from its core operations. It indicates how efficiently the company is managing its production costs and pricing its products.

The total revenue of Moleculin Biotech Inc (MBRX) represents the amount of money the company has generated from all its business activities. It includes the revenue from the sale of goods or services, as well as any other income the company receives. This figure is important because it shows the company's ability to generate sales and grow its business. It also provides insights into the company's market position and the demand for its products or services.

The net debt of Moleculin Biotech Inc (MBRX) is the difference between the company's total debt and its cash equivalents. It represents the amount of money the company owes after considering its available cash balance. This figure is important because it shows the company's financial solvency and its ability to meet its debt obligations. A high net debt can indicate financial risk, while a low net debt can indicate financial stability.

The cash equivalents of Moleculin Biotech Inc (MBRX) represent highly liquid assets that can be readily converted into cash. These include short-term investments, such as treasury bills, money market funds, and certificates of deposit. Cash equivalents are important because they provide a measure of the company's liquidity and its ability to meet short-term financial obligations. They can also be used as a source of funding for the company's operations or investments.

The total assets of Moleculin Biotech Inc (MBRX) represent the value of all the company's resources, including cash, inventory, property, equipment, and intangible assets. This figure is important because it shows the company's financial strength and its ability to generate future cash flows. It also provides insights into the company's investment in its business and its potential for growth.

The total debt of Moleculin Biotech Inc (MBRX) represents the amount of money the company owes to its creditors and lenders. This includes long-term and short-term debt, such as bank loans, bonds, and lines of credit. Total debt is important because it indicates the company's level of financial leverage and its ability to meet its debt obligations. A high total debt can indicate financial risk, while a low total debt can indicate financial stability.

The total liabilities of Moleculin Biotech Inc (MBRX) represent the company's obligations and debts to third parties. This includes both short-term liabilities, such as accounts payable and accrued expenses, and long-term liabilities, such as long-term debt and pension obligations. Total liabilities are important because they show the company's level of financial risk and its ability to meet its financial obligations. They also indicate the company's reliance on external financing and its potential vulnerability to economic downturns.

The free cash flow of Moleculin Biotech Inc (MBRX) is the cash generated by the company's operations after deducting capital expenditures and working capital changes. It represents the amount of cash available to the company for distribution to investors, debt repayment, or reinvestment in the business. Free cash flow is important because it shows the company's ability to generate cash from its operations and its potential for future growth. It is a key metric used by investors to assess the company's financial health and value.

In summary, Moleculin Biotech Inc (MBRX) financials provide valuable insights into the company's financial performance, position, and cash flows. These metrics help investors assess the company's profitability, liquidity, solvency, and growth potential. They provide a comprehensive view of the company's financial health and can guide investment decisions.

Please note that the information provided above is for educational purposes only and should not be considered as financial advice. Investors should conduct their own research and analysis before making investment decisions.